Atherosclerosis Treatment Drugs Market : Consumption, Revenue And Key Players GlaxoSmithKline ,Merck., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals

Increasing number of pipeline studies and rising involvement of key players for developing the treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in August 2021.

Moreover, technological advancement in the atherosclerosis treatment procedures is expected to boost the atherosclerosis treatments drug market growth. For instance, in May 2017, Researchers at Ben-Gurion University (BGU) and the Sheba Medical Center developed Nano polymer therapy, a new therapy for the treatment of atherosclerosis. It prevents heart failure with a new biomedical polymer (E-selectin-targeting polymer) that reduces arterial plaque and inflammation in the cardiovascular system. E-selectin-targeting polymer helps to reduce existing plaque and impedes the further plaque formation. It also prevents arterial thrombosis, ischemia, myocardial infarction, and strokes.

Get HOLISTIC Request Sample Copy Of This Business Report:https://www.coherentmarketinsights.com/insight/request-sample/2430

Atherosclerosis Treatment Drugs Market- Restraints

However, the side effects associated with atherosclerosis drugs and limited efficacy of the drugs is expected to hamper atherosclerosis market growth. For instance, in November 2016, The Lancet led by Rory Collins, provided an evidence on statin therapy and the methodological limitations. As per data, statins are associated with increased incidence of diabetes and hemorrhagic stroke. Statins tends to increase the risk of type 2 diabetes in a dose-dependent mode.

Atherosclerosis Treatment Drugs Market- Regional Analysis

On the basis of region, the global atherosclerosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is expected to gain significant market share over the forecast period, owing to increasing incidences of atherosclerotic condition among the population in this region. For instance, in November 2016, as per data provided by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), there were more than 15.5 million Americans who had coronary artery disease and it is expected that for every 42 seconds an American will experience the onset of a myocardial infarction.

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to expansion of major key players in this region. For instance, in October 2017, GSK opened its new regional headquarters for Asia in Singapore. The GSK’s purpose for building headquarters is to support the pharmaceutical, vaccines, and consumer healthcare businesses across multiple regions in Asia Pacific.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2430

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.